Clinical Report: Efficacy of Ixekizumab Alone or Combined with Tirzepatide
Overview
The TOGETHER-PsO trial evaluated the efficacy and safety of ixekizumab alone versus in combination with tirzepatide in patients with moderate to severe psoriasis and overweight or obesity.
Background
Psoriasis is frequently associated with overweight and obesity, affecting 60% to 78% of patients. This comorbidity complicates treatment outcomes and increases the risk of psoriatic arthritis and cardiovascular issues.
Data Highlights
Group
Complete Skin Clearance
Weight Reduction
Ixekizumab + Tirzepatide
27%
≥10%
Ixekizumab Alone
6%
≥10%
Key Findings
The combination of ixekizumab and tirzepatide achieved a primary endpoint of superiority in skin clearance and weight loss.
27% of patients on combination therapy achieved complete skin clearance and at least 10% weight reduction at 36 weeks.
Only 6% of patients receiving ixekizumab alone achieved the same outcomes.
The trial was conducted at 72 sites in the US and included adults with moderate to severe plaque psoriasis.
No new safety concerns were reported with the combination therapy.
Clinical Implications
The findings suggest that combining ixekizumab with tirzepatide may enhance treatment efficacy for patients with psoriasis and obesity. Clinicians should consider this combination therapy to improve patient outcomes in this population.
Conclusion
The TOGETHER-PsO trial demonstrates that ixekizumab combined with tirzepatide offers significant benefits in managing psoriasis and obesity, warranting further exploration in clinical practice.
by Mark Lebwohl, Andrew Blauvelt, Cynthia E. Kartman, Cianna Leatherwood, Kenneth B. Gordon, Naveed Sattar, Luis Puig, Joseph F. Merola, Kimberly Siu, Rona Wang, Luna Sun, Ann Leung, Najwa Somani, Maria Jose Rueda, Anabela Cardoso, Mark C. Genovese, April W. Armstrong, Bruce Strober
